Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy

doi:10.3748/wjg.v22.i19.4685

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4460)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

475

WORD

306

HTML

3470

Figures (1-6)

209

Sum=4460

May 21, 2016 (publication date) through Jul 18, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. May 21, 2016; 22(19): 4685-4694
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4685

Full Size Figure Download Figure

Figure 2 QT interval in control and CCl₄-induced cirrhotic rats treated with normal saline or rapamycin (2 mg/kg). QT intervals were defined as corrected QT (QT_c) using Bazett’s formula. The data are expressed as the mean ± SD. ^eP < 0.001 vs control/normal saline group; ^bP < 0.01 vs control/rapamycin and cirrhotic/saline group.

Citation: Saeedi Saravi SS, Ghazi-Khansari M, Ejtemaei Mehr S, Nobakht M, Mousavi SE, Dehpour AR. Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy. World J Gastroenterol 2016; 22(19): 4685-4694
URL: https://www.wjgnet.com/1007-9327/full/v22/i19/4685.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i19.4685